Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Eupraxia Pharmaceuticals Inc. (T:EPRX)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEDAR
Company Contact
Address: 2067 Cadboro Bay Road, #201
Tel: N/A
IR: See website
Key People
Business Overview
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company with a drug delivery technology platform. The Company's lead product candidate EP-104IAR, is developed for the treatment long-lasting pain relief for knee osteoarthritis (OA). In addition to EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. The Company's pipeline candidates include a range of drugs for indications such as post-surgical anesthetic (EP-105) and post-surgical site infections (EP-201). The Company is also engaged in the development of candidates to its pipeline including an internally developed oncology product. The Company is also engaged in developing a formulation of EP-104IAR for use in canine and equine OA.
Financial Overview
For the six months ended 30 June 2021, EupraxiaPharmaceuticals Inc revenues was not reported. Net lossincreased from C$2.8M to C$14.3M. Higher net loss reflectsResearch and development increase from C$789K to C$4.3M(expense), Stock-based compensation increase from C$108K toC$3.2M (expense), Loss on conversion of notes and specialincrease from C$0K to C$2.3M (expense).
Reporting Currency: Canadian Dollars
Enterprise value: $54.71M as of Jun 30, 2021
Annual revenue (TTM): $0.00M as of Jun 30, 2021
EBITDA (TTM): -$10.61M as of Jun 30, 2021
Net annual income (TTM): -$15.49M as of Jun 30, 2021
Free cash flow (TTM): N/A
Net Debt Last Fiscal Year: N/A
Shares outstanding: 14,242,595 as of Jun 30, 2021
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization